Preclinical profile of GM102, a first-in-class antibody targeting AMHRII in ovarian cancers.

e23196Background: Expression of anti-Mullerian hormone receptor (AMHRII) is described in gynecologic cancers, tumors which are largely infiltrated by immune myeloid cells. Based on these observatio...